LLDT-67 attenuates MPTP-induced neurotoxicity in mice by up-regulating NGF expression

Acta Pharmacologica Sinica

Volumn 33, Issue 9, 2012, Pages 1187-1194

  Wu, Dong Dong ^a   Huang, Li ^a   Zhang, Lei ^a   Wu, Le Yu ^a   Li, Yuan Chao ^a   Feng, Linyin ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

dopaminergic neurons; LLDT 67; MPTP; neuroprotection; NGF; Parkinson's disease; striatum; substantia nigra; triptolide; TrkA

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; LLDT 67; MONOAMINE; NERVE GROWTH FACTOR; NEUROPROTECTIVE AGENT; PROTEIN KINASE B; PROTEIN TYROSINE KINASE A; TRIPTOLIDE; TYROSINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BEHAVIOR CHANGE; BRAIN LEVEL; CONTROLLED STUDY; CORPUS STRIATUM; DRUG MECHANISM; ENZYME PHOSPHORYLATION; EXPERIMENTAL TEST; FORCED SWIMMING TEST; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MOUSE; NERVE CELL CULTURE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OPEN FIELD TEST; PARKINSON DISEASE; POLE TEST; SUBSTANTIA NIGRA; UPREGULATION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANIMALS, NEWBORN; ASTROCYTES; CELLS, CULTURED; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DITERPENES; DOPAMINERGIC NEURONS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; MICE, INBRED C57BL; NERVE GROWTH FACTOR; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; PHENANTHRENES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, TRKA; SUBSTANTIA NIGRA; TIME FACTORS; UP-REGULATION;

EID: 84865982605     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2012.88     Document Type: Article

References (33)

1. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973; 20: 415-55.
2. Agid Y. Parkinson's disease: pathophysiology. Lancet 1991; 337: 1321-4.
3. Ren YX, Zhou R, Tang W, Wang WH, Li YC, Yang YF, et al. (5R)-5-hydroxytriptolide (LLDT-8) protects against bleomycin-induced lung fibrosis in mice. Acta Pharmacol Sin 2007; 28: 518-25. (Pubitemid 46496079)
4. Zhao F, Chen Y, Zeng LL, Li R, Zeng R, Wen L, et al. Effects of triptolide on RIZ1 expression, proliferation, and apoptosis in multiple myeloma U266 cells. Acta Pharmacol Sin 2010; 31: 733-40.
5. Wen L, Chen Y, Zeng LL, Zhao F, Li R, Liu Y, et al. Triptolide induces cell-cycle arrest and apoptosis of human multiple myeloma cells in vitro via altering expression of histone demethylase LSD1 and JMJD2B. Acta Pharmacol Sin 2012; 33: 109-19.
6. Li FQ, Cheng XX, Liang XB, Wang XH, Xue B, He QH, et al. Neurotrophic and neuroprotective effects of tripchlorolide, an extract of Chinese herb Tripterygium wilfordii Hook F, on dopaminergic neurons. Exp Neurol 2003; 179: 28-37. (Pubitemid 36062616)
7. Meredith GE, Sonsalla PK, Chesselet MF. Animal models of Parkinson's disease progression. Acta Neuropathol 2008; 115: 385-98.
8. Przedborski S, Jackson-Lewis V, Naini AB, Jakowec M, Petzinger G, Miller R, et al. The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J Neurochem 2001; 76: 1265-74. (Pubitemid 32198231)
9. Matsuura K, Kabuto H, Makino H, Ogawa N. Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. J Neurosci Methods 1997; 73: 45-8. (Pubitemid 27166123)
10. Kato H, Kurosaki R, Oki C, Araki T. Arundic acid, an astrocytemodulating agent, protects dopaminergic neurons against MPTP neurotoxicity in mice. Brain Res 2004; 1030: 66-73. (Pubitemid 39563827)
11. Meredith GE, Kang UJ. Behavioral models of Parkinson's disease in rodents: a new look at an old problem. Mov Disord 2006; 21: 1595-606. (Pubitemid 44742185)
12. Menet V, Gimenez y Ribotta M, Chauvet N, Drian MJ, Lannoy J, Colucci-Guyon E, et al. Inactivation of the glial fibrillary acidic protein gene, but not that of vimentin, improves neuronal survival and neurite growth by modifying adhesion molecule expression. J Neurosci 2001; 21: 6147-58. (Pubitemid 32737747)
13. Titov DV, Gilman B, He QL, Bhat S, Low WK, Dang Y, et al. XPB, a subunit of TFIIH, is a target of the natural product triptolide. Nat Chem Biol 2011; 7: 182-8.
14. Wang Y, Lu JJ, He L, Yu Q. Triptolide (TPL) inhibits global transcription by inducing proteasome-dependent degradation of RNA polymerase II (Pol II). PLoS One 2011; 6: e23993.
15. Meng HT, Zhu L, Ni WM, You LS, Jin J, Qian WB. Triptolide inhibits the proliferation of cells from lymphocytic leukemic cell lines in association with downregulation of NF-kappaB activity and miR-16-1. Acta Pharmacol Sin 2011; 32: 503-11.
16. Qiu D, Zhao G, Aoki Y, Shi L, Uyei A, Nazarian S, et al. Immunosuppressant PG490 (triptolide) inhibits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated T-cells and NFkappaB transcriptional activation. J Biol Chem 1999; 274: 13443-50.
17. Phillips PA, Dudeja V, McCarroll JA, Borja-Cacho D, Dawra RK, Grizzle WE, et al. Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70. Cancer Res 2007; 67: 9407-16. (Pubitemid 47535931)
18. Freeman RS, Burch RL, Crowder RJ, Lomb DJ, Schoell MC, Straub JA, et al. NGF deprivation induced gene expression: after ten years, where do we stand? Prog Brain Res 2004; 146: 111-26. (Pubitemid 37541379)
19. Madduri S, Papaloizos M, Gander B. Synergistic effect of GDNF and NGF on axonal branching and elongation in vitro. Neurosci Res 2009; 65: 88-97.
20. Wang WX, Hu XY, Xie XJ, Liu XB, Wu RR, Wang YP, et al. Nerve growth factor induces cord formation of mesenchymal stem cell by promoting proliferation and activating the PI3K/Akt signaling pathway. Acta Pharmacol Sin 2011; 32: 1483-90.
21. Crowder RJ, Freeman RS. Phosphatidylinositol 3-kinase and Akt protein kinase are necessary and sufficient for the survival of nerve growth factor-dependent sympathetic neurons. J Neurosci 1998; 18: 2933-43. (Pubitemid 28163223)
22. McMahon SB, Priestley JV. Peripheral neuropathies and neurotrophic factors: animal models and clinical perspectives. Curr Opin Neurobiol 1995; 5: 616-24.
23. Tuszynski MH, Thal L, Pay M, Salmon DP, U HS, Bakay R, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005; 11: 551-5. (Pubitemid 40691288)
24. Shimoke K, Chiba H. Nerve growth factor prevents 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced cell death via the Akt pathway by suppressing caspase-3-like activity using PC12 cells: relevance to therapeutical application for Parkinson's disease. J Neurosci Res 2001; 63: 402-9. (Pubitemid 32183789)
25. Thorne RG, Frey WH. Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin Pharmacokinet 2001; 40: 907-46. (Pubitemid 34066688)
26. Miller G. Drug targeting. Breaking down barriers. Science 2002; 297: 1116-8. (Pubitemid 36193322)
27. Chen XQ, Fawcett JR, Rahman YE, Ala TA, Frey IW. Delivery of nerve growth factor to the brain via the olfactory pathway. J Alzheimers Dis 1998; 1: 35-44.
28. Tuszynski MH, Thal L, U HS, Pay MM, Blesch A, Conner J, et al. Nerve growth factor gene therapy for Alzheimer's disease. J Mol Neurosci 2002; 19: 207. (Pubitemid 35021253)
29. Saragovi HU, Gehring K. Development of pharmacological agents for targeting neurotrophins and their receptors. Trends Pharmacol Sci 2000; 21: 93-8. (Pubitemid 30114323)
30. Kaplan DR, Miller FD. Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol 2000; 10: 381-91. (Pubitemid 30389307)
31. Culmsee C, Gerling N, Lehmann M, Nikolova-Karakashian M, Prehn JH, Mattson MP, et al. Nerve growth factor survival signaling in cultured hippocampal neurons is mediated through TrkA and requires the common neurotrophin receptor P75. Neuroscience 2002; 115: 1089-108. (Pubitemid 35351700)
32. Huang EJ, Reichardt LF. Trk receptors: roles in neuronal signal transduction. Annu Rev Biochem 2003; 72: 609-42. (Pubitemid 36930455)
33. Xiao J, Liu Y. Differential roles of ERK and JNK in early and late stages of neuritogenesis: a study in a novel PC12 model system. J Neurochem 2003; 86: 1516-23. (Pubitemid 37174268)